ME Therapeutics Holdings Inc. Receives Funding Support for Preclinical Testing of Prodrug Candidates

ME Therapeutics Holdings Inc. is a Canada-based biotechnology company. The Company is involved in the discovery and development of novel immuno oncology therapeutics targeting immune suppression in cancer. The Company’s lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. This antibody drug candidate is being developed to treat colorectal cancer. In addition, to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. Its two development programs include its anti-G-CSF antibody and its myeloid target prodrug and are engaged in a discovery program to discover novel lipid nanoparticle formulations. Its anti-G-CSF antibody candidate (h1B11-12) is its advanced preclinical asset.